Lorlatinib before surgery for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking lorlatinib before surgery can shrink or control early-stage lung cancer that has a specific genetic change (ALK). It aims to improve surgical outcomes and reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of lung cancer called adenocarcinoma that has the ALK gene change.
- Your cancer is at an early stage (IB to IIIB) and can be removed with surgery.
- You have not had any previous treatment for this lung cancer.
- You are in good overall health (able to perform daily activities) and your heart, lungs, liver, and kidneys are working well enough for surgery and study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a newer targeted pill (lorlatinib) with standard chemoradiation (chemo plus radiation) for people with stage III ALK-positive lung adenocarcinoma. The goal is to see if lorlatinib alone works better than standard treatment and causes fewer side effects.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Hear when a new Neoadjuvant Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.